Status:
COMPLETED
RIVastigmine In Vascular cognitivE Impairment
Lead Sponsor:
Singapore General Hospital
Collaborating Sponsors:
Novartis
National Neuroscience Institute
Conditions:
Cognitive Impairment
Eligibility:
All Genders
55-85 years
Phase:
PHASE4
Brief Summary
The study is a 24-week prospective, double blind, randomized, placebo-controlled pilot study of 9 mg / day Rivastigmine in patients with Vascular Cognitive Impairment Not Dementia (CIND) to evaluate e...
Detailed Description
Methodology: This is a 24-week, double blind, randomized, placebo-controlled pilot study of 9 mg / day Rivastigmine in patients with Cognitive Impairment Not Dementia due to cerebrovascular disease. ...
Eligibility Criteria
Inclusion
- male and female patients, age 55-85
- outpatients, living with a caregiver
- Rankin score \<=3
- Diagnosis of Cognitive Impairment Not Dementia due to cerebrovascular disease
- Post-stroke cognitive impairment
- Cognitive impairment documented by neuropsychological evaluation within 6 months of index stroke
Exclusion
- Advanced, severe, and unstable disease of any type that may interfere with the efficacy evaluations or put the subject at special risk
- A current diagnosis of active uncontrolled seizure disorder
- A current diagnosis of active peptic ulceration
- A current diagnosis of severe and unstable cardiovascular disease
- A current diagnosis of sick-sinus syndrome or conduction deficits (sino-atrial block, atrioventricular block)
- A current diagnosis of unstable angina
- MI within the last 6 months
- DSM IV current diagnosis of dementia
- DSM IV current diagnosis of major depression (patients may be included if currently being treated on an antidepressant and stabilized after 3 months)
- A disability that may prevent the subject from completing all study requirements (e.g. blindness, deafness, severe language difficulty)
- A known exaggerated pharmacological sensitivity or hypersensitivity to acetylcholinesterase inhibitors or to other cholinergic compounds
- Ingestion of any of the following:
- an investigational drug in the past four weeks
- metrifonate in the last 3 months
- a drug or treatment known to cause major organ system toxicity during the past four weeks
- other cholinergic drugs (eg succinylcholine type muscle relaxants) during the past two weeks
- anticholinergics prior to baseline
- acetylcholinesterase inhibitors in the past 3 months
- Women of childbearing potential
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00669344
Start Date
February 1 2006
End Date
February 1 2008
Last Update
February 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Singapore General Hospital
Singapore, Singapore, 169608